|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
156,320,000 |
Market
Cap: |
6.65(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$20.26 - $43.27 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Cerevel Therapeutics Holdings is a clinical-stage biopharmaceutical company. Co.'s programs: Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype; Darigabat, which is a PAM that selectively targets the alpha-2/3/5 subunits of the GABAA receptor; Tavapadon, which is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of early- and late-stage Parkinson's disease; and CVL-871, which is a selective dopamine D1/D5 receptor partial agonist specifically designed to achieve a level of partial agonism.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
17,422,701 |
18,847,701 |
Total Buy Value |
$0 |
$0 |
$397,510,553 |
$447,385,553 |
Total People Bought |
0 |
0 |
6 |
6 |
Total Buy Transactions |
0 |
0 |
6 |
7 |
Total Shares Sold |
154,667 |
359,132 |
611,027 |
1,200,893 |
Total Sell Value |
$6,418,967 |
$14,072,755 |
$21,003,717 |
$39,590,443 |
Total People Sold |
2 |
8 |
8 |
10 |
Total Sell Transactions |
5 |
21 |
27 |
48 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Coles N Anthony |
CEO and Chairperson |
|
2023-05-04 |
4 |
AS |
$31.36 |
$1,573,434 |
D/D |
(50,000) |
2,704 |
|
-28% |
|
Coles N Anthony |
CEO and Chairperson |
|
2023-05-04 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
|
- |
|
Coles N Anthony |
CEO and Chairperson |
|
2023-04-11 |
4 |
AS |
$25.06 |
$1,253,130 |
D/D |
(50,000) |
2,704 |
|
-17% |
|
Coles N Anthony |
CEO and Chairperson |
|
2023-04-11 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
|
- |
|
Coles N Anthony |
CEO and Chairperson |
|
2023-03-03 |
4 |
AS |
$27.19 |
$81,570 |
D/D |
(3,000) |
2,704 |
|
8% |
|
Coles N Anthony |
CEO and Chairperson |
|
2023-03-03 |
4 |
OE |
$3.50 |
$10,500 |
D/D |
3,000 |
5,704 |
|
- |
|
Coles N Anthony |
CEO and Chairperson |
|
2023-03-02 |
4 |
AS |
$27.11 |
$1,274,377 |
D/D |
(47,000) |
2,704 |
|
12% |
|
Coles N Anthony |
CEO and Chairperson |
|
2023-03-02 |
4 |
OE |
$3.50 |
$164,500 |
D/D |
47,000 |
49,704 |
|
- |
|
Coles N Anthony |
CEO and Chairperson |
|
2023-02-07 |
4 |
AS |
$33.04 |
$1,656,401 |
D/D |
(50,000) |
2,704 |
|
2% |
|
Coles N Anthony |
CEO and Chairperson |
|
2023-02-07 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
|
- |
|
Coles N Anthony |
CEO and Chairperson |
|
2022-12-09 |
4 |
AS |
$26.62 |
$1,333,300 |
D/D |
(50,000) |
2,704 |
|
4% |
|
Coles N Anthony |
CEO and Chairperson |
|
2022-12-09 |
4 |
OE |
$3.50 |
$175,000 |
D/D |
50,000 |
52,704 |
|
- |
|
Renger John |
Chief Scientific Officer |
|
2022-11-01 |
4 |
AS |
$30.00 |
$750,005 |
D/D |
(25,000) |
2,704 |
|
-17% |
|
Renger John |
Chief Scientific Officer |
|
2022-11-01 |
4 |
OE |
$3.50 |
$189,078 |
D/D |
25,000 |
27,704 |
|
- |
|
Renger John |
Chief Scientific Officer |
|
2022-10-04 |
4 |
AS |
$30.00 |
$750,000 |
D/D |
(25,000) |
2,704 |
|
11% |
|
Renger John |
Chief Scientific Officer |
|
2022-10-04 |
4 |
OE |
$3.50 |
$189,078 |
D/D |
25,000 |
27,704 |
|
- |
|
Patrick Deval L |
Director |
|
2022-09-12 |
4 |
AS |
$30.78 |
$1,468,422 |
D/D |
(47,705) |
0 |
|
7% |
|
Patrick Deval L |
Director |
|
2022-09-12 |
4 |
OE |
$12.62 |
$602,037 |
D/D |
47,705 |
47,705 |
|
- |
|
Ceesay Abraham |
President |
|
2022-09-08 |
4 |
AS |
$32.50 |
$624,325 |
D/D |
(19,210) |
0 |
|
2% |
|
Ceesay Abraham |
President |
|
2022-09-08 |
4 |
OE |
$13.17 |
$252,996 |
D/D |
19,210 |
19,210 |
|
- |
|
Ceesay Abraham |
President |
|
2022-08-22 |
4 |
AS |
$32.50 |
$312,163 |
D/D |
(9,605) |
0 |
|
-5% |
|
Ceesay Abraham |
President |
|
2022-08-22 |
4 |
OE |
$13.17 |
$126,498 |
D/D |
9,605 |
9,605 |
|
- |
|
Edelman Joseph |
Director |
|
2022-08-16 |
4 |
B |
$35.00 |
$49,875,000 |
I/I |
1,425,000 |
6,511,727 |
2.1 |
-8% |
|
Ceesay Abraham |
President |
|
2022-08-15 |
4 |
AS |
$34.12 |
$327,757 |
D/D |
(9,606) |
0 |
|
-14% |
|
Ceesay Abraham |
President |
|
2022-08-15 |
4 |
OE |
$13.17 |
$126,511 |
D/D |
9,606 |
9,606 |
|
- |
|
181 Records found
|
|
Page 4 of 8 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|